Get the Stockscreener App
13.13
0.23%
0.03
After Hours:
13.00
-0.13
-0.99%
Crescent Biopharma Inc stock is traded at $13.13, with a volume of 144.46K.
It is up +0.23% in the last 24 hours and up +16.30% over the past month.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
See More
Previous Close:
$13.10
Open:
$13.11
24h Volume:
144.46K
Relative Volume:
1.27
Market Cap:
$219.85M
Revenue:
$6.67M
Net Income/Loss:
$-47.55M
P/E Ratio:
-8.7533
EPS:
-1.5
Net Cash Flow:
$-17.44M
1W Performance:
+2.98%
1M Performance:
+16.30%
6M Performance:
+2,468%
1Y Performance:
+2,468%
1-Day Range:
$12.87
$13.20
1-Week Range:
$12.00
$13.20
52-Week Range:
$9.81
$21.40
Crescent Biopharma Inc Stock (CBIO) Company Profile
Name
Crescent Biopharma Inc
Sector
Industry
Phone
617-430-5595
Address
300 FIFTH AVENUE, WALTHAM, CA
Compare CBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CBIO
Crescent Biopharma Inc
|
13.13 | 219.85M | 6.67M | -47.55M | -17.44M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.50B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Crescent Biopharma Inc Stock (CBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-25-25 | Initiated | Jefferies | Buy |
| Aug-11-25 | Initiated | H.C. Wainwright | Buy |
| Jul-14-25 | Initiated | Wedbush | Outperform |
| Jun-25-25 | Initiated | Stifel | Buy |
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-11-25 | Initiated | Noble Capital Markets | Outperform |
| Jul-26-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-22-23 | Initiated | CapitalOne | Overweight |
| Nov-12-21 | Upgrade | Jefferies | Hold → Buy |
| Apr-29-21 | Resumed | Stephens | Overweight |
| Feb-10-21 | Initiated | Piper Sandler | Overweight |
| May-21-20 | Initiated | Raymond James | Outperform |
| Nov-14-19 | Initiated | ROTH Capital | Buy |
| Aug-05-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-05-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-05-19 | Downgrade | SunTrust | Buy → Hold |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Jan-04-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-18 | Initiated | H.C. Wainwright | Buy |
| Feb-12-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Feb-09-18 | Reiterated | Chardan Capital Markets | Buy |
| Dec-08-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Jun-12-17 | Initiated | Chardan Capital Markets | Buy |
| Jun-06-17 | Initiated | Ladenburg Thalmann | Buy |
| Jul-26-16 | Initiated | SunTrust | Buy |
| Jun-30-16 | Initiated | Rodman & Renshaw | Buy |
| Mar-17-15 | Reiterated | Stifel | Buy |
View All
Crescent Biopharma Inc Stock (CBIO) Latest News
What valuation ratios show for Crescent Biopharma Inc. (GKO0) stockMarket Risk Report & Fast Moving Stock Watchlists - newser.com
What market sentiment indicators show for Crescent Biopharma Inc. (GKO0) stockTreasury Yields & Community Verified Swing Trade Signals - newser.com
Crescent Biopharma Advances Cancer Therapy Pipeline - TipRanks
Crescent Biopharma: Q3 Earnings Snapshot - Stamford Advocate
Crescent Biopharma Reports Third Quarter 2025 Financial Results and Recent Business Highlights - The Manila Times
CRESCENT BIOPHARMA, INC. SEC 10-Q Report - TradingView
Is Crescent Biopharma Inc. (GKO0) stock expanding market penetrationWeekly Trade Review & Trade Opportunity Analysis Reports - newser.com
Is Crescent Biopharma Inc. (GKO0) stock a top hedge fund pickQuarterly Market Review & Comprehensive Market Scan Reports - newser.com
Crescent Biopharma to Present at November Investor Conferences - The Manila Times
Crescent Biopharma (NASDAQ: CBIO) sets November investor talks; webcasts, 90-day replay - Stock Titan
Will Crescent Biopharma Inc. (GKO0) stock top growth indexesMarket Activity Report & Entry Point Confirmation Signals - newser.com
Crescent Biopharma, Inc. to Present Preclinical Data for CR-001, a PD-1 X VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer's 40th Annual Meeting - MarketScreener
Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting - Stock Titan
Crescent Biopharma (NASDAQ:CBIO) Stock Crosses Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Crescent BiopharmaLighting The Path To The Next Wave Of Cancer Therapies? - RTTNews
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Crescent Biopharma, Inc. (NASDAQ:CBIO) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Crescent Biopharma Inc Stock (CBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.44%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):